Artificial intelligence gives new hope for sufferers of severe heart problem

New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.
Merilyn Oakes and Professor Michael Feneley. Picture: John Feder

Remy Varga

Artificial intelligence gives new hope for sufferers of severe heart problem

April 20, 2023
New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.
Read Transcript

New artificial intelligence software can improve the diagnosis of severe aortic stenosis by 72 per cent and could potentially change the lives of about 50,000 Australians with the life-threatening condition who are misdiagnosed each year.

The EchoSolv diagnostic software identified more than twice as many cases of the disease, a narrowing of the heart valve, than humans, according to research conducted by St Vincent’s hospitals in Sydney and Melbourne that compiled more than 9000 studies.

St Vincent‘s Hospital Cardiology and Heart Lung Program director Michael Feneley said the research found 218 human-found patients with the condition compared to 442. “It turns out we humans only found about half of the patients with severe aortic stenosis in the sample and the AI found the rest,” he said.

Currently cardiologists diagnose severe aortic stenosis by manually reviewing dozens of echocardiograms, which are pictures of the heart, to identify about a dozen common problems.

About half of severe conditions and more than two-thirds of cases in women are missed under current diagnostic methods.

University of Notre Dame professor Geoff Strange, the principal investigator on the research, said in Australia there were about 100,000 patients with a treatable form of the disease and about a quarter of a million with some kind of valvular disease. “We’re treating about 10,000 – that’s a big deficit of patients,” he said.

Prof Strange said the EchoSolv addressed misdiagnosis by reviewing measurements collected during a cardiac ultrasound, the most common procedure to detect valvular heart disease, and painting a picture of the condition of the heart.

“It gives a probability output in about 1.5 seconds for the clinician to know whether the patient in front of them has a high probability of severe aortic stenosis,” he said.

Prof Strange said the study had identified a number of biases in diagnosis including around symptoms and gender, with the condition going undetected in women compared to men.

“The reason this is overcome by artificial intelligence is because it doesn’t have any unconscious bias,” he said.

Merilyn Oaks, 81, was diagnosed with severe aortic stenosis in December 2020 and last week had her aortic valve replaced with a catheter.

Use of the EchoSolve technology could have detected her condition earlier but Ms Oaks said she was grateful for technological advancements that allowed her more time with her seven grandkids.

“Only a few of the older ones actually know I’ve had this procedure but they’re very keen for me to be around for as long as I possibly can,” she said.

“For me that’s a very good thing.”

Prof Feneley has been treating Ms Oaks and said she was the type of patient who could benefit from the EchoSolve and save her from undergoing invasive diagnostic procedures.

“I had to do quite an invasive procedure on her,” he said.

“I put an ultrasound probe down the oesophagus so I could get closer to the heart valve and managed to get an image of the valve where I can actually measure how narrow it was directly with an image.”

 

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 20 April 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

New artificial intelligence software can improve the diagnosis of severe aortic stenosis by 72 per cent and could potentially change the lives of about 50,000 Australians with the life-threatening condition who are misdiagnosed each year.

The EchoSolv diagnostic software identified more than twice as many cases of the disease, a narrowing of the heart valve, than humans, according to research conducted by St Vincent’s hospitals in Sydney and Melbourne that compiled more than 9000 studies.

St Vincent‘s Hospital Cardiology and Heart Lung Program director Michael Feneley said the research found 218 human-found patients with the condition compared to 442. “It turns out we humans only found about half of the patients with severe aortic stenosis in the sample and the AI found the rest,” he said.

Currently cardiologists diagnose severe aortic stenosis by manually reviewing dozens of echocardiograms, which are pictures of the heart, to identify about a dozen common problems.

About half of severe conditions and more than two-thirds of cases in women are missed under current diagnostic methods.

University of Notre Dame professor Geoff Strange, the principal investigator on the research, said in Australia there were about 100,000 patients with a treatable form of the disease and about a quarter of a million with some kind of valvular disease. “We’re treating about 10,000 – that’s a big deficit of patients,” he said.

Prof Strange said the EchoSolv addressed misdiagnosis by reviewing measurements collected during a cardiac ultrasound, the most common procedure to detect valvular heart disease, and painting a picture of the condition of the heart.

“It gives a probability output in about 1.5 seconds for the clinician to know whether the patient in front of them has a high probability of severe aortic stenosis,” he said.

Prof Strange said the study had identified a number of biases in diagnosis including around symptoms and gender, with the condition going undetected in women compared to men.

“The reason this is overcome by artificial intelligence is because it doesn’t have any unconscious bias,” he said.

Merilyn Oaks, 81, was diagnosed with severe aortic stenosis in December 2020 and last week had her aortic valve replaced with a catheter.

Use of the EchoSolve technology could have detected her condition earlier but Ms Oaks said she was grateful for technological advancements that allowed her more time with her seven grandkids.

“Only a few of the older ones actually know I’ve had this procedure but they’re very keen for me to be around for as long as I possibly can,” she said.

“For me that’s a very good thing.”

Prof Feneley has been treating Ms Oaks and said she was the type of patient who could benefit from the EchoSolve and save her from undergoing invasive diagnostic procedures.

“I had to do quite an invasive procedure on her,” he said.

“I put an ultrasound probe down the oesophagus so I could get closer to the heart valve and managed to get an image of the valve where I can actually measure how narrow it was directly with an image.”

 

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 20 April 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Disclaimer: This material has been prepared by The Australian, published on Apr 20, 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
August 19, 2021

The Florey: Innovative new approach for Parkinson’s disease

Florey researchers have partnered with engineers from ANU to develop and study a new type of hydrogel that could radically transform a novel stem cell treatment for Parkinson’s disease.

Read More
August 10, 2021

Podcast: Minding Your Mind

Prof Ian Hickie, of the Brain and Mind Centre has launched a podcast, Minding Your Mind, to explore all aspects of mental health; the different types of mental health issues we can experience, their causes, how they affect us, and what we can do to get help and find solutions.

Read More
August 3, 2021

Australian breakthrough to stop heart arteries from clogging

Victor Chang scientist has led landmark research that has the potential to stop arteries of the heart from becoming clogged by targeting a particular gene.

Read More
July 16, 2021

Victor Chang: Discovery of live-saving heart attack treatment

New research out of Victor Chang brings treatment for Australia’s biggest killer a step closer, this exciting discovery could lead to new preventative treatments for atherosclerosis and coronary artery disease.

Read More
February 23, 2021

Podcast: Paul Rayson, Mental Wellth

This episode of Mental Wellth looks at how mental health is funded and Paul Rayson discusses how vehicles like Hearts and Minds are an emerging funding solution.

Read More
December 9, 2020

Beneficiary Profile: MS Research Australia

MS Research Australia is the largest non-government funder of research into multiple sclerosis (MS). They have invested over $44.3m into MS research via major collaborative research platforms and investigator-led projects.

Read More
November 23, 2020

Thank you from MS Research Australia

MS Research Australia has a message of thanks to the Hearts and Minds Community for the support we provide them and their research to Stop and Reverse MS within the next 10 years.

Read More
October 12, 2020

Beneficiary Profile: Victor Chang

Cardiovascular disease is the number one cause of death globally and costs the Australian economy $12 billion each year. Every 12 minutes, one Australian dies from the disease. This is why the Victor Chang Cardiac Research Institute is dedicated to finding cures through their world class research.

Read More
September 27, 2020

Thank you from Prof Pat McGorry, Orygen

Professor Pat McGorry, Executive Director of Orygen has a message of thanks to Cooper Investors and HM1 shareholders for the support we provide them and their research into the mental health of young people.

Read More
September 25, 2020

The ASX company championing hearts and minds

Swinburne’s Centre for Human Psychopharmacology is honoured to have been selected by one of Hearts and Minds’ fund managers, Cooper Investors, as a recipient of funding.

Read More
September 23, 2020

Silent wave' of brain damage could follow pandemic

Australia urgently needs to prepare for a "silent wave" of COVID-19, which appears to be taking the form of long-term neurological side effects following infection with the virus.

Read More
September 8, 2020

Beneficiary Profile: Black Dog Institute

1 in 5 of us will experience symptoms of mental illness in any given year. In Australia that’s around 5 million people. And roughly 60% of these people won’t seek help. Learn what Black Dog is doing to create a mentally healthier world for everyone.

Read More
September 1, 2020

ABC: Cash for Causes

An increasing number of LICs are being created to spit out cash for causes. HM1 is such a LIC that top fund managers donate their time too. This year it paid out $9.3m to medical research. HM1's Chairman Chris Cuffe, speaks to Elysse Morgan on ABC's The Business.

Read More
September 1, 2020

Hearts and Minds donates almost $10m to charity

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 medical research this week, in addition to the $4.1 million it already donated in March. [Financial Standard]

Read More
September 1, 2020

Hearts and Minds keep shining the light on medical research

CEO Paul Rayson says HM1's results are outstanding given the bumpy period. COVID-19 has shone a light on medical research and he's proud to contribute to the field and help support people during these tough times.

Read More